Literature DB >> 21278327

Jewish ethnicity and pancreatic cancer mortality in a large U.S. cohort.

Ronald C Eldridge1, Susan M Gapstur, Christina C Newton, Michael Goodman, Alpa V Patel, Eric J Jacobs.   

Abstract

BACKGROUND: An association between Jewish ethnicity and pancreatic cancer risk was suggested by analyses comparing pancreatic cancer mortality rates between Jews and non-Jews in New York in the 1950s. These analyses lacked information on potential confounding factors and the association between Jewish ethnicity and pancreatic cancer has not been examined in any contemporary U.S. population or in any cohort study.
METHODS: We examined the association between Jewish ethnicity and pancreatic cancer mortality among approximately 1 million participants in the Cancer Prevention Study II cohort. Participants completed a questionnaire at enrollment in 1982 which included information on religion, smoking, obesity, and diabetes. During follow-up through 2006, there were 6,727 pancreatic cancer deaths, including 480 among Jewish participants. Proportional hazards modeling was used to calculate multivariable rate ratios (RR).
RESULTS: After adjusting for age, sex, smoking, body mass index, and diabetes, pancreatic cancer mortality was higher among Jewish participants than among non-Jewish whites (RR = 1.43; 95% CI, 1.30-1.57). In analyses by birthplace, RRs were 1.59 (95% CI, 1.31-1.93) for North American-born Jews with North American-born parents, 1.43 (95% CI, 1.27-1.61) for North American-born Jews with 1 or more parents born outside North America, and 1.03 (0.73, 1.44) for Jews born outside North America (P(heterogeneity) = 0.07).
CONCLUSIONS: These results support a higher risk of developing pancreatic cancer among U.S. Jews that is not explained by established risk factors. IMPACT: Future studies may clarify the role of specific environmental or genetic factors responsible for higher risk among U.S. Jews.

Entities:  

Mesh:

Year:  2011        PMID: 21278327     DOI: 10.1158/1055-9965.EPI-10-1196

Source DB:  PubMed          Journal:  Cancer Epidemiol Biomarkers Prev        ISSN: 1055-9965            Impact factor:   4.254


  6 in total

1.  Detectable Symptomatology Preceding the Diagnosis of Pancreatic Cancer and Absolute Risk of Pancreatic Cancer Diagnosis.

Authors:  Harvey A Risch; Herbert Yu; Lingeng Lu; Mark S Kidd
Journal:  Am J Epidemiol       Date:  2015-06-06       Impact factor: 4.897

2.  Impact of Sixteen Established Pancreatic Cancer Susceptibility Loci in American Jews.

Authors:  Samantha A Streicher; Alison P Klein; Sara H Olson; Laufey T Amundadottir; Andrew T DeWan; Hongyu Zhao; Harvey A Risch
Journal:  Cancer Epidemiol Biomarkers Prev       Date:  2017-07-28       Impact factor: 4.254

3.  African-Americans and Indigenous Peoples Have Increased Burden of Diseases of the Exocrine Pancreas: A Systematic Review and Meta-Analysis.

Authors:  Aya Cervantes; Ellen K Waymouth; Maxim S Petrov
Journal:  Dig Dis Sci       Date:  2018-09-27       Impact factor: 3.199

4.  A pooled genome-wide association study identifies pancreatic cancer susceptibility loci on chromosome 19p12 and 19p13.3 in the full-Jewish population.

Authors:  Samantha A Streicher; Alison P Klein; Sara H Olson; Robert C Kurtz; Laufey T Amundadottir; Andrew T DeWan; Hongyu Zhao; Harvey A Risch
Journal:  Hum Genet       Date:  2020-07-15       Impact factor: 4.132

5.  Targeting DNA Damage Repair Mechanisms in Pancreas Cancer.

Authors:  Lukas Perkhofer; Talia Golan; Pieter-Jan Cuyle; Tamara Matysiak-Budnik; Jean-Luc Van Laethem; Teresa Macarulla; Estelle Cauchin; Alexander Kleger; Alica K Beutel; Johann Gout; Albrecht Stenzinger; Eric Van Cutsem; Joaquim Bellmunt; Pascal Hammel; Eileen M O'Reilly; Thomas Seufferlein
Journal:  Cancers (Basel)       Date:  2021-08-24       Impact factor: 6.639

6.  Case-control study of aspirin use and risk of pancreatic cancer.

Authors:  Samantha A Streicher; Herbert Yu; Lingeng Lu; Mark S Kidd; Harvey A Risch
Journal:  Cancer Epidemiol Biomarkers Prev       Date:  2014-07       Impact factor: 4.090

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.